CREBBP and cancer: HIF-1 is an emerging, but not yet fully validated target for cancer chemotherapy; the interaction of HIF-1α with CREB binding protein (CBP)/p300 plays a major role in regulating the hypoxic response and as such its inhibition represents an attractive approach to prevent development of new vasculature by hypoxic tumours.